These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38070635)

  • 21. Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic.
    Chakraborty A; Pang J; Chan DC; Barnett W; Woodward AM; Vorster M; Watts GF
    Clin Cardiol; 2021 Jun; 44(6):805-813. PubMed ID: 33955565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
    Bergmark BA; O'Donoghue ML; Murphy SA; Kuder JF; Ezhov MV; Ceška R; Gouni-Berthold I; Jensen HK; Tokgozoglu SL; Mach F; Huber K; Gaciong Z; Lewis BS; Schiele F; Jukema JW; Pedersen TR; Giugliano RP; Sabatine MS
    JAMA Cardiol; 2020 Jun; 5(6):709-713. PubMed ID: 32347887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
    Tsai CL; Chang YH; Su CH; Wu YJ; Yeh HI; Lin CF
    J Formos Med Assoc; 2022 Sep; 121(9):1877-1880. PubMed ID: 34852937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
    Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
    Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):31-38. PubMed ID: 33063111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
    Liang D; Li C; Tu Y; Li Z; Zhang M
    Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
    Marston NA; Gurmu Y; Melloni GEM; Bonaca M; Gencer B; Sever PS; Pedersen TR; Keech AC; Roselli C; Lubitz SA; Ellinor PT; O'Donoghue ML; Giugliano RP; Ruff CT; Sabatine MS
    Circulation; 2020 May; 141(20):1600-1607. PubMed ID: 32223429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery.
    Akiyama T; Ozaki K; Takano T; Yoneyama S; Kubota N; Okubo T; Ikegami R; Hoyano M; Yanagawa T; Inomata T
    Intern Med; 2023 Nov; 62(22):3361-3365. PubMed ID: 37005262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).
    Zhang X; Stiekema LCA; Stroes ESG; Groen AK
    Lipids Health Dis; 2020 May; 19(1):91. PubMed ID: 32393252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
    O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
    Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
    Atia A; Aboeldahab H; Wageeh A; Elneny M; Elmallahy M; Elawfi B; Aboelkhier MM; Elrosasy A; Abdelwahab MM; Sayed S; Abdelaziz A
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):83-102. PubMed ID: 38241002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of proprotein convertase subtilisin/kexin type 9 inhibitor on blood lipid profile in patients with extremely high risk atherosclerotic cardiovascular disease].
    Wang J; Deng S; Liu Y; She Q; Du J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Mar; 32(3):341-344. PubMed ID: 32386000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.